Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 582 shares, a decline of 96.2% from the August 15th total of 15,394 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 61,763 shares, the days-to-cover ratio is currently 0.0 days.

Revelation Biosciences Stock Performance

REVB traded down $0.01 during trading on Friday, hitting $0.99. 2,979 shares of the stock were exchanged, compared to its average volume of 266,070. The firm has a 50 day simple moving average of $1.06 and a 200 day simple moving average of $1.11. The firm has a market cap of $3.95 million, a price-to-earnings ratio of -0.08 and a beta of -0.14. Revelation Biosciences has a 1 year low of $0.88 and a 1 year high of $8.04.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. As a group, equities analysts anticipate that Revelation Biosciences will post -5.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revelation Biosciences

Large investors have recently modified their holdings of the business. Geode Capital Management LLC purchased a new stake in shares of Revelation Biosciences in the 4th quarter worth approximately $27,000. Armistice Capital LLC bought a new position in Revelation Biosciences in the third quarter worth approximately $114,000. Finally, Sabby Management LLC lifted its holdings in Revelation Biosciences by 192.5% during the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after buying an additional 398,651 shares during the period. Institutional investors own 12.80% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, August 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Revelation Biosciences presently has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.